Physician profile
Camilo Jimenez
NPI 1275614372
$14,373.20
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $6,422 · 2021: $938 · 2022: $2,374 · 2023: $4,265 · 2024: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,622 · Travel and Lodging: $1,594 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $237 · Food and Beverage: $49.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,622.00 |
| Travel and Lodging | $1,594.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $236.84 |
| Food and Beverage | $49.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $6,048.86 | 2019-2023 | Azedra |
| Merck Sharp & Dohme LLC | $4,687.50 | 2020-2023 | Welireg |
| Hra Pharma Rare Diseases | $3,400.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $236.84 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilo Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.